http://www.cryocath.com Toronto Stock Exchange Symbol: CYT
MONTREAL, May 1 /PRNewswire-FirstCall/ - CryoCath (TSX: CYT), will hold
a conference call to discuss its second quarter 2008 financial results at
4:30 p.m. (Eastern Time) on Monday, May 12, 2008. The Company will report
its results in a press release to be issued at 4:00 p.m. on Monday, May 12.
DATE: Monday, May 12, 2008
TIME: 4:30 p.m., Eastern Standard Time
TAPED REPLAY: 416-640-1917 or 1-877-289-8525
(Available until May 19, 2008)
REFERENCE NUMBER: 21270226
WEBCAST: A live audio webcast of the call will be available at
http://www.cryocath.com. Webcast attendees are welcome to listen to
the conference in real-time or on-demand at their convenience.
The webcast will be archived for 365 days. Please connect to
this website at least 15 minutes prior to the conference call
to ensure adequate time for any software download that may be
needed to hear the webcast.
CryoCath - http://www.cryocath.com - is a medical technology company that leads the world in cryotherapy products to treat cardiac arrhythmias. With a priority focus on providing physicians with a complete solution of catheter products to treat cardiac arrhythmias, CryoCath has multiple products approved in the U.S., across Europe and several ROW countries. The Company is developing additional products to expand its pipeline of products to treat cardiac arrhythmias.
This press release includes "forward-looking statements" that are subject to risks and uncertainties, including with respect to the timing of regulatory trials and their outcome. For information identifying legislative or regulatory, economic, climatic, currency, technological, competitive and other important factors that could cause actual results to differ materially from those anticipated in the forward looking statements, see CryoCath's annual report available at http://www.sedar.com under the heading Risks and Uncertainties in the Management's Discussion and Analysis section.
|SOURCE CryoCath Technologies Inc.|
Copyright©2008 PR Newswire.
All rights reserved